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RARβ and SIRT1 present in regions of 
the brain most relevant to AD, such as the 
hippocampus? Would the Aβ-lowering 
effect of RARβ agonism, which is only 
partial, be sufficient to prevent or treat 
AD? What other genes are affected by 
RARβ activation, and how might they 
alter the AD phenotype? As for Notch 
signaling, the initiating step is the bind-
ing of ligand, not ectodomain shedding 
by ADAM10. Would elevation of ADAM10 
alone be sufficient to increase Notch sig-
naling in vivo? If so, would this lead to 
neuronal repair in the AD brain? Is there 
a natural ligand of APP that initiates 
shedding of the APP ectodomain, and 
would manipulating this ligand provide 
a more focused approach to increasing 
α-secretase processing of APP and thus 
reducing Aβ production? Perhaps most 
importantly, ADAM10 sheds the ectodo-
mains of many type I integral membrane 
proteins at the cell surface. What are 
the consequences, both beneficial and 
toxic, of chronically increasing ADAM10 
activity in the brain and in the periphery? 
Such questions are now worth address-
ing to assess whether this new approach 
will ultimately be able to deliver a payoff 
punch to AD.
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545–555.Four genes in the human genome have 
the SRD5A acronym, but only two of 
them, SRD5A1 and SRD5A2, encode a 
bona fide steroid 5α-reductase. The other 
two genes, SRD5A3 and SRD5A2L2, 
are posers, claiming the name despite 
having little or no functional ability to 
reduce steroid substrates. What then 
are the true substrates of these two 
pretenders? In this issue of Cell, Can-
tagrel et al. (2010) ingeniously combine 
analytical chemistry with genetics in 
humans, mice, and yeast to uncover 
the enzymatic and biological function 
of steroid 5α-reductase SRD5A3. They 
demonstrate that SRD5A3 encodes a 
polyprenol reductase that is essential 
for N-linked glycosylation of proteins in 
yeast and mammals (Figure 1A), a com-
pletely unexpected function.
SRD5A1 and SRD5A2 reduce the ∆4,5 
bond of steroid substrates using NADPH 
as a cofactor (Figure 1B) (Russell and 
Wilson, 1994). It seems that any gene 
with even a remote sequence similarity to 
SRD5A1 and SRD5A2 (such as SRD5A3, 
SRD5A2L, and others that do not use 
the SRD5A prefix) has been included in 
this family (Langlois et al., 2010). How-
ever, aside from one study on the enzy-
matic activity of SRD5A3 (Uemura et al., 
2008), experimental data on these pro-
teins has been lacking, and it is unclear 
whether steroids are indeed substrates 
of SRD5A3 and SRD5A2L.
For most steroid hormones including 
progestins and glucocorticoids, reduc-
tion of the ∆4,5 bond inactivates tran-
scriptional signaling by the hormone. 
One critical exception to this general rule 
is the reduction of the ∆4,5 bond in tes-
tosterone to produce dihydrotestoster-
one (Figure 1B). This reaction is of great 
importance during the sexual develop-
ment of males because only dihydrotes-
tosterone (not testosterone) directs the 
formation and growth of the external 
genitalia and prostate (Wilson, 1978).
Surprisingly, Cantagrel et al. (2010) find 
that steroid 5α-reductase SRD5A3 is not 
involved in steroid hormone formation or 
sexual development but instead plays a 
crucial role in the N-linked glycosylation 
of proteins. Their study begins with an 
astute clinical observation. Four children 
of a large family were born with multiple 
developmental anomalies of the eyes, 
heart, and brain. A family history revealed 
several consanguineous relationships, 
suggesting that the disease was auto-
sRD5A3: A surprising Role in Glycosylation
Ashlee R. Stiles1 and David W. Russell1,*
1Department of Molecular Genetics, University of Texas Southwestern Medical Center, Dallas, TX 75390-9046, USA
*Correspondence: david.russell@utsouthwestern.edu
DOI 10.1016/j.cell.2010.07.003
The steroid 5α-reductase (SRD5A) family of enzymes produces steroid hormones that regulate 
male sexual development. Now, Cantagrel et al. (2010) identify a member of this family, SRD5A3, 
as a polyprenol reductase with a crucial role in N-linked protein glycosylation and pinpoint SRD5A3 
mutations as the cause of a rare Mendelian disease.196 Cell 142, July 23, 2010 ©2010 Elsevier Inc.
somal recessive. Consistent 
with this mode of inheri-
tance, genome-wide linkage 
analysis and DNA sequenc-
ing identified a homozygous 
mutation in the SRD5A3 
gene. Analysis of individuals 
with similar symptoms from 
unrelated families uncovered 
six additional mutations in 
SRD5A3. The numerous phe-
notypes (i.e., the pleiotropy) 
arising from these mutations 
strikingly resembled those 
of patients with congenital 
disorders of glycosylation, a 
group of recessively inherited 
diseases caused by defects 
in N-linked protein glycosyla-
tion.
N-linked protein glycosyla-
tion involves the addition of 
a 14 sugar glycan to select 
asparagine residues on a 
nascent protein to facilitate 
the proper folding and traf-
ficking of the protein. Occur-
ring in the membrane of the 
endoplasmic reticulum (ER), 
N-linked protein glycosyla-
tion is a byzantine process 
that involves many steps 
(Figure 1A). These include the 
assembly of a lipid carrier for 
the oligosaccharide, the flip-
flopping of this lipid between 
leaflets of the ER membrane, 
and multiple cycles of phos-
phorylation and dephospho-
rylation of lipids. The large 
number of players in the path-
way renders the genetics of 
congenital disorders of glyco-
sylation complex. Moreover, 
major deficiencies in N-linked 
glycosylation have dire con-
sequences in many organ 
systems because the major-
ity of proteins, both secreted 
and membrane-bound, are substrates 
for this crucial modification.
The similarity of the phenotypes 
observed for individuals with mutations 
in SRD5A3 and patients with congenital 
disorders of glycosylation suggested to 
Cantagrel and colleagues that SRD5A3 
encodes a key enzyme in the pathway 
of N-linked protein glycosylation. But 
which enzyme? This is a difficult ques-
tion to address given the intricacy of the 
pathway and complexity of its chemistry. 
In the end, Cantagrel et al. used many 
types of cutting-edge mass spectrom-
etry to show that SRD5A3 reduces the 
terminal double bond of polyprenols to 
form dolichols (Figure 1A). Furthermore, 
this reduction is required for assembling 
the complex glycolipids that 
donate polysaccharides dur-
ing N-linked glycosylation. 
Specifically, dolichols in the 
ER membrane are phosphory-
lated and tagged with a glycan 
unit, which is subsequently 
transferred to an asparagine 
residue by the activity of oligo-
saccharyl transferases (Figure 
1A).
At this point, Cantagrel 
and colleagues had discov-
ered the molecular basis of a 
genetic disease and uncov-
ered the function of an SRD5A 
family member, but this was 
just the start. They go on to 
demonstrate that SRD5A3 
is also required for N-linked 
glycosylation in many dif-
ferent organisms. Deletion 
of the Srd5a3 gene in mice 
disrupted protein glycosyla-
tion and resulted in death of 
mouse embryos. Interestingly, 
deletion of Srd5a3 in mice 
also boosted the expression 
of enzymes in the mevalonate 
pathway, which synthesize 
the building blocks of poly-
prenols, the substrates of 
SRD5A3 (Figure 1A).
In the model plant Arabi-
dopsis thaliana, mutations 
in the steroid 5α-reductase 
gene DET2 cause dwarf-
ism and render male plants 
sterile. Furthermore, these 
defects are rescued by human 
SRD5A1 or SRD5A2 (Li et 
al., 1997). This conservation 
of function across the great 
evolutionary divide between 
primates and plants was 
unique when reported. Can-
tagrel and colleagues now 
describe similarly impres-
sive conservation. They show 
that human SRD5A3 rescues glycosyla-
tion defects in the budding yeast Sac-
charomyces cerevisiae. Moreover, this 
property is unique to SRD5A3 because 
none of the other members of the ste-
roid 5α-reductase family accomplish this 
task, including the trans-2,3-enoyl-CoA 
reductase (TECR). Indeed, Cantagrel 
et al. could not detect any polyprenol 
figure 1. steroid 5α-Reductase and N-Linked Protein Glycosylation
(A) The addition of a 14 sugar oligosaccharide to nascent proteins (N-linked 
glycosylation) occurs in the membrane of the endoplasmic reticulum (ER), 
where dolichol-phosphate (Dol-P) serves as a lipid carrier for the glycan unit. 
The steroid 5α-reductase SRD5A3 catalyzes the reduction of the terminal 
double bond of polyprenols to generate dolichols, the precursor of Dol-P 
(Cantagrel et al., 2010). Mutations in SRD5A3 cause a congenital disorder of 
glycosylation leading to severe developmental anomalies in humans.
(B) The other four human steroid 5α-reductase enzymes also reduce the 
double bond of various lipid substrates using the NADPH cofactor. SRD5A1 
and SRD5A2 are required for the proper sexual development of males by 
catalyzing the synthesis of dihydrotestosterone from testosterone. Although 
the trans-2,3-enoyl-CoA reductase (TECR) is known to operate on fatty acids, 
the substrate(s) for the trans-2,3-enoyl-CoA reductase-like (TECRL) enzyme 
is unknown.Cell 142, July 23, 2010 ©2010 Elsevier Inc. 197
reductase activity for TECR (GPSN2), 
confirming an earlier study, which had 
identified fatty acids as the substrates of 
this steroid 5α-reductase family member 
(Figure 1B) (Moon and Horton, 2003).
The work of Cantagrel and coworkers 
is creatively exhaustive and nails down 
every aspect of a difficult research prob-
lem from yeast cultures to the clinic. 
Where could they possibly go from here? 
For one, their studies in mice with muta-
tions in Srd5a3 suggest a regulatory 
crosstalk between the mevalonate path-
way and N-linked protein glycosylation, 
and it will be interesting to determine the 
mechanism underlying this interplay. In 
addition, the substrate and physiological 
function of SRD5A2L are still unknown. 
Will this steroid 5α-reductase function in 
glycosylation or hormone production, or 
will it play a completely distinct role from 
that of its namesake?
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Bone remodeling is a highly conserved 
and regulated process that controls 
calcium homeostasis within a very tight 
range and maintains the structural integ-
rity of the skeleton. In this issue of Cell, 
tandem articles from independent labo-
ratories (Fulzele et al., 2010; Ferron et 
al., 2010) provide fresh support for the 
hypothesis that the insulin regulatory sys-
tem mediates communication between 
metabolic control and bone remodeling. 
Fulzele et al. (2010) provide compelling in 
vivo evidence, using conditional deletion 
of the insulin receptor in osteoblasts, 
that insulin signaling promotes bone 
formation by suppressing an inhibi-
tor of osteoblast development, Twist2, 
and enhances expression of osteocal-
cin, a mediator of insulin sensitivity and 
secretion. Ferron et al. (2010) show that 
insulin signaling in osteoblasts mediates 
glucose homeostasis by stimulating the 
production of an inactive form of osteo-
calcin and by promoting osteoclast-
mediated bone resorption, which then 
releases the active form of osteocalcin. 
In this putative feed-forward loop, the 
complete bone remodeling process is 
involved, thereby linking skeletal homeo-
stasis to energy regulation. Given that 
the findings from these papers may have 
profound implications for understanding 
and ultimately treating several metabolic 
conditions, a closer examination of these 
two reports is necessary to clarify where 
and how this regulatory loop is situated 
in the hierarchy of control mechanisms 
that define insulin signaling and bone 
turnover.
It has only been a decade since Ducy 
et al. (2000) demonstrated that leptin (an 
adipokine that regulates appetite, energy 
expenditure, and insulin secretion) influ-
ences bone remodeling through hypo-
thalamic modulation of the sympathetic 
nervous system. Prior to that, skeletal 
remodeling was considered within its 
essential context of calcium conserva-
tion, a homeostatic process regulated 
by calciotropic hormones (such as 
parathyroid hormone and vitamin D), 
gonadal steroids (such as estrogen), and 
local growth factors (such as insulin-like 
growth factor I and transforming growth 
factor β). Subsequent work has provided 
stronger support for the tenet that lep-
tin is a major, albeit indirect, mediator 
of skeletal turnover through neuronal 
circuits in the central nervous system 
(Lee et al., 2007; Yoshizawa et al., 2009). 
In addition the osteoblast-specific pro-
tein osteocalcin is reported to promote 
insulin secretion (Hinoi et al., 2008; Fer-
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Advancing the hypothesis that bone remodeling is intimately linked to metabolic homeostasis, 
Fulzele et al. (2010) and Ferron et al. (2010) present evidence that insulin signaling promotes 
the activation of bone-forming osteoblasts and enhances production of osteocalcin, a secreted 
mediator of insulin sensitivity, through modulation of bone resorption.
